摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-(2,6-dimethylbenzyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | 345665-22-7

中文名称
——
中文别名
——
英文名称
(R)-N-(2,6-dimethylbenzyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
英文别名
(4R)-N-[(2,6-dimethylphenyl)methyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
(R)-N-(2,6-dimethylbenzyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide化学式
CAS
345665-22-7
化学式
C15H22N2OS
mdl
——
分子量
278.418
InChiKey
GZPLAHMQKLMVDX-CYBMUJFWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    66.4
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Structure–activity and structure–metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure
    摘要:
    A series of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing substituted allophenyinorstatine [Apns: (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid] were designed and synthesized. From the structure-metabolism relationship of this type of HIV protease inhibitors, the compounds having para substitution of the phenyl ring of Apris and/or 2,6-disubstitution of the P2' benzylamine were found to be able to avoid the P2 phenol glucuronidation that occurs with SM-319777 (formerly named JE-2147, KNI-764); one of the main metabolic pathways of SM-319777. These new analogues, such as SM-322377, had more desirable pharmacokinetic profiles and more potent antiviral activity against not only wild type HIV-1 but also the multi-drug-resistant HIV-1 than SM-319777. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2003.10.037
  • 作为产物:
    参考文献:
    名称:
    Structure–activity and structure–metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure
    摘要:
    A series of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing substituted allophenyinorstatine [Apns: (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid] were designed and synthesized. From the structure-metabolism relationship of this type of HIV protease inhibitors, the compounds having para substitution of the phenyl ring of Apris and/or 2,6-disubstitution of the P2' benzylamine were found to be able to avoid the P2 phenol glucuronidation that occurs with SM-319777 (formerly named JE-2147, KNI-764); one of the main metabolic pathways of SM-319777. These new analogues, such as SM-322377, had more desirable pharmacokinetic profiles and more potent antiviral activity against not only wild type HIV-1 but also the multi-drug-resistant HIV-1 than SM-319777. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2003.10.037
点击查看最新优质反应信息

文献信息

  • Structure–activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure
    作者:Tsutomu Mimoto、Satoshi Nojima、Keisuke Terashima、Haruo Takaku、Makoto Shintani、Hideya Hayashi
    DOI:10.1016/j.bmc.2007.10.062
    日期:2008.2.1
    A series of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing substituted allophenylnorstatine (Apns: (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid) were designed and synthesized. From the structure-activity relationship of this series of compounds, SM-309515 was found to have potent antiviral activity against wild-type and resistant HIV-1s and to possess a desirable
    设计并合成了一系列含有取代的别基去甲他汀(Apns:(2S,3S)-3-基-2-羟基-4-羟基丁酸)的拟肽类人免疫缺陷病毒(HIV)蛋白酶抑制剂。从该系列化合物的构效关系,发现SM-309515对野生型和抗性HIV-1具有有效的抗病毒活性,并在犬中具有理想的药代动力学特征。
  • Novel dipeptide compounds and their use as medicines
    申请人:——
    公开号:US20020049165A1
    公开(公告)日:2002-04-25
    A novel dipeptide compound inhibiting the enzymatic activity of HIV protease, an anti-AIDS medicine comprising this dipeptide compound as an effective component. The dipeptide compound is the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof 1 wherein R 1 , R 2 , and R 3 independently represent a linear or branched, saturated or unsaturated lower alkyl group, alkoxyl group, alkyl amino group, or dialkyl amino group having 1-4 carbon atoms (with a carbon atom being either replaced by an oxygen atom or not), a halogeno group, or a hydrogen atom, provided that all of the R 1 , R 2 , and R 2 are not a hydrogen atom at the same time, R 2 and R 3 may form a ring together, R 4 represents a linear or branched lower alkyl group having 1-4 carbon atoms or a hydrogen atom; X is a methylene group or a sulfur atom; Y represents a five or six member monocyclic or polycyclic hydrocarbon group, a heterocyclic group having a structure in which one or more carbon atom in the monocyclic or polycyclic hydrocarbon group is replaced by a hetero atom, an aryloxy group having 12 or less carbon atoms, in which the aromatic ring may be substituted with an alkyl group, alkoxy group, halogeno group, amino group or hydroxyl group; and Z represents an aliphatic hydrocarbon group having 1-6 carbon atoms or an aromatic hydrocarbon group having 12 or less carbon atoms in which the aromatic ring may be substituted with an alkyl group, alkoxy group, or halogeno group, or one or more carbon atom in the aromatic hydrocarbon group may be replaced by a hetero atom.
    一种新型二肽化合物,能够抑制HIV蛋白酶的酶活性,一种抗艾滋病药物,其中包括该二肽化合物作为有效成分。该二肽化合物是由式(I)表示的化合物或其药学上可接受的盐,其中R1、R2和R3独立地表示线性或支链、饱和或不饱和的低基、烷基、烷基基或二烷基基,其原子数为1-4个(其中一个原子被原子替换或未被替换),卤素基或原子,前提是R1、R2和R3不能同时为原子,R2和R3可以一起形成环,R4表示线性或支链低基或原子;X表示亚甲基基团或原子;Y表示五元或六元单环或多环烃基,具有一种结构,其中单环或多环烃基中的一个或多个原子被杂原子取代,具有12个或更少原子的芳基,其中芳环可以用烷基、烷基、卤素基、基或羟基取代;Z表示具有1-6个原子的脂肪烃基或具有12个或更少原子的芳香烃基,其中芳环可以用烷基、烷基或卤素基取代,或者芳香烃基中的一个或多个原子可以被杂原子取代。
  • NOVEL DIPEPTIDE COMPOUND AND MEDICINAL USE THEREOF
    申请人:JAPAN ENERGY CORPORATION
    公开号:EP1157997A1
    公开(公告)日:2001-11-28
    A novel dipeptide compound inhibiting the enzymatic activity of HIV protease, an anti-AIDS medicine comprising this dipeptide compound as an effective component. The dipeptide compound is the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, and R3 independently represent a linear or branched, saturated or unsaturated lower alkyl group, alkoxyl group, alkyl amino group, or dialkyl amino group having 1-4 carbon atoms (with a carbon atom being either replaced by an oxygen atom or not), a halogeno group, or a hydrogen atom, provided that all of the R1, R2, and R3 are not a hydrogen atom at the same time, R2 and R3 may form a ring together, R4 represents a linear or branched lower alkyl group having 1-4 carbon atoms or a hydrogen atom; X is a methylene group or a sulfur atom; Y represents a five or six member monocyclic or polycyclic hydrocarbon group, a heterocyclic group having a structure in which one or more carbon atom in the monocyclic or polycyclic hydrocarbon group is replaced by a hetero atom, an aryloxy group having 12 or less carbon atoms, in which the aromatic ring may be substituted with an alkyl group, alkoxy group, halogeno group, amino group or hydroxyl group; and Z represents an aliphatic hydrocarbon group having 1-6 carbon atoms or an aromatic hydrocarbon group having 12 or less carbon atoms in which the aromatic ring may be substituted with an alkyl group, alkoxy group, or halogeno group, or one or more carbon atom in the" aromatic hydrocarbon group may be replaced by a hetero atom.
    一种抑制 HIV 蛋白酶酶活性的新型二肽化合物,一种以该二肽化合物为有效成分的抗艾滋病药物。该二肽化合物是式 (I) 所代表的化合物或其药学上可接受的盐 其中 R1、R2 和 R3 独立地代表具有 1-4 个原子的直链或支链、饱和或不饱和低级烷基、烷基、烷基基或具有 1-4 个原子的二烷基基(原子可以被原子取代,也可以不被原子取代)、卤素基团或原子,条件是所有的 R1、R2 和 R3 不是同时为原子,R2 和 R3 可以一起形成一个环,R4 代表具有 1-4 个原子的直链或支链低级烷基或原子;X 是亚甲基原子;Y 代表五元或六元单环或多环烃基、杂环基(其结构中单环或多环烃基的一个或多个原子被杂原子取代)、芳基(具有 12 个或更少原子),其中芳环可被烷基、烷基、卤素基、基或羟基取代;Z 代表具有 1-6 个原子的脂肪族烃基或具有 12 个或更少原子的芳香族烃基,其中芳香环可被烷基、烷基或卤代基团取代,或 "芳香族烃基 "中的一个或多个原子可被杂原子取代。
  • US6673772B2
    申请人:——
    公开号:US6673772B2
    公开(公告)日:2004-01-06
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸